European Tech Sovereignty

The Tech Sovereignty Package did not adopt on 27 May as promised; it slipped a third time to a tentative 3 June after the US ambassador called it a red line. France now chairs the G7 in two days with nothing to table. Mistral buys into industrial AI while wearing a USTR target, and the digital euro becomes the one instrument still on schedule.

Europe's tech sovereignty machine enters a 10-day delivery window. On 27 May the Commission adopts the Cloud and AI Development Act alongside a revamped Chips Act. On 29 May France chairs the G7 Digital Ministerial at Bercy. The 7 May AI Omnibus deal has already split the AI Act enforcement clock in two.

Two weeks after Sovereign Tech Europe declared sovereignty moving from concept to construction, the construction came from a trade body and a retail conglomerate. The Commission's tech-sovereignty package slipped to 27 May. Seven European CEOs, Mistral included, told von der Leyen on 5 May to stop adding rules.

The inaugural Sovereign Tech Europe summit opened in Brussels today with 45 speakers, no European AI model companies, and only cabinet-level Commission presence. In one week the machinery of European sovereignty has become visible: four named cloud providers, seven DSIT investees, an open DMA consultation. Every instrument carries a US dependency somewhere inside it.

Europe and Britain converted sovereignty rhetoric into binding instruments in a single week: a €180m pan-EU sovereign cloud framework, the first UK Sovereign AI investees including defence-AI firm Cosine, and a DMA order forcing Google to share search data by 27 July. The three mechanisms expose a structural contradiction between shared European dependency, national British isolation, and an uncoordinated regulatory calendar.

Two of the EU Chips Act's three flagship fabs have stalled, leaving the bloc's 20% global market share target effectively dead. Mistral is building Europe's closest thing to a sovereign AI champion, but the continent's sovereignty gap remains an implementation gap: the right diagnosis, the right prescriptions, and an 11.2% delivery rate.